EA202191370A1 - PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS PREPARATION - Google Patents

PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS PREPARATION

Info

Publication number
EA202191370A1
EA202191370A1 EA202191370A EA202191370A EA202191370A1 EA 202191370 A1 EA202191370 A1 EA 202191370A1 EA 202191370 A EA202191370 A EA 202191370A EA 202191370 A EA202191370 A EA 202191370A EA 202191370 A1 EA202191370 A1 EA 202191370A1
Authority
EA
Eurasian Patent Office
Prior art keywords
carbon atoms
pharmaceutical composition
group
alkyl group
represent
Prior art date
Application number
EA202191370A
Other languages
Russian (ru)
Inventor
Тацуя Мураками
Такехиро Ямане
Сироу СОНОКЕ
Ацуси Кано
Со Тойонага
Original Assignee
Фуджифилм Корпорэйшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фуджифилм Корпорэйшн filed Critical Фуджифилм Корпорэйшн
Publication of EA202191370A1 publication Critical patent/EA202191370A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

Настоящее изобретение обеспечивает фармацевтическую композицию, включающую смесь, содержащую по меньшей мере одно аморфное вещество, выбранное из соединения, представленного общей формулой (I), его соли и гидрата, а также водорастворимый полимер на основе целлюлозы; и пористые неорганические частицы, при этом фармацевтическая композиция содержит от 1 до 20 частей по массе пористых неорганических частиц на 100 частей по массе фармацевтической композиции; и способ получения указанных веществ. В общей формуле (I) R1 и R2 представляют собой атом водорода, аминогруппу, алкильную группу, имеющую от 1 до 4 атомов углерода, или т.п.; R3 и R5 представляют собой атом водорода, алкильную группу, содержащую от 1 до 4 атомов углерода, или т.п.; R4 представляет собой алкильную группу, содержащую от 1 до 4 атомов углерода, алкенильную группу, содержащую от 2 до 4 атомов углерода, алкинильную группу, содержащую от 2 до 4 атомов углерода, цианогруппу, -CH=CH-CN или атом галогена; X1 представляет собой -NH-, -O- или -S-.The present invention provides a pharmaceutical composition comprising a mixture containing at least one amorphous substance selected from a compound represented by the general formula (I), a salt and a hydrate thereof, and a water-soluble cellulose-based polymer; and porous inorganic particles, the pharmaceutical composition containing from 1 to 20 parts by weight of porous inorganic particles per 100 parts by weight of the pharmaceutical composition; and a method for producing said substances. In the general formula (I), R1 and R2 represent a hydrogen atom, an amino group, an alkyl group having 1 to 4 carbon atoms, or the like; R3 and R5 represent a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, or the like; R4 is an alkyl group of 1 to 4 carbon atoms, an alkenyl group of 2 to 4 carbon atoms, an alkynyl group of 2 to 4 carbon atoms, a cyano group, —CH = CH — CN, or a halogen atom; X1 is -NH-, -O- or -S-.

EA202191370A 2018-12-14 2019-12-13 PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS PREPARATION EA202191370A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018234688 2018-12-14
PCT/JP2019/049018 WO2020122242A1 (en) 2018-12-14 2019-12-13 Pharmaceutical composition and method for producing same

Publications (1)

Publication Number Publication Date
EA202191370A1 true EA202191370A1 (en) 2021-09-16

Family

ID=71076508

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191370A EA202191370A1 (en) 2018-12-14 2019-12-13 PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS PREPARATION

Country Status (2)

Country Link
EA (1) EA202191370A1 (en)
WO (1) WO2020122242A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101790371A (en) * 2007-06-25 2010-07-28 泰博特克药品公司 Comprise the combination preparation that reaches that Wei of reed and comply with bent Wei Lin
SG190618A1 (en) * 2008-05-02 2013-06-28 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
EP2306980A2 (en) * 2008-06-30 2011-04-13 Tibotec Pharmaceuticals Powders for reconstitution
WO2015136294A1 (en) * 2014-03-13 2015-09-17 Cipla Limited Pharmaceutical composittion comprising rilpivirine
TWI765410B (en) * 2014-08-08 2022-05-21 日商中外製藥股份有限公司 Use of amorphous body of tetracyclic compound

Also Published As

Publication number Publication date
WO2020122242A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
AR028531A1 (en) ORGANIC COMPOUNDS
BR0112856A (en) Method for treating the disorder, compound or a salt or solvate thereof, process for preparing the disorder, pharmaceutical composition, method of treatment and / or prophylaxis of one or more of the disorders, use of a compound, and method for treatment of diabetes, major depression, manic depression, anxiety, schizophrenia, and sleep disorders in human and non-human mammals
ATE431345T1 (en) AZABICYCLO-(3,1,0)-HEXANE DERIVATIVES SUITABLE AS MODULATORS OF DOPAMINE D3 RECEPTORS
BR122012009489B8 (en) process for producing 2-ethoxy-1-{[2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazol- (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 7-carboxylate or a salt thereof, pharmaceutical composition, and use
MXPA05011710A (en) Fused pyrimidine derivatives with crf activity.
WO2003080580A3 (en) Quinoline derivatives and their use as 5-ht6 ligands
AR060316A1 (en) UTILITY AZAINDOLS AS INHIBITORS OF JANUS QUINASAS
PH12014501033A1 (en) Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ATE530066T1 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
HUP9801357A2 (en) Imidazoline-, imidazole-, oxazoline and thiazoline derivatives, pharmaceutical compositions containing them and process for producing them
PE20050420A1 (en) PHENACILO 2-HYDROXY-3-DIAMINOALKANOS
MX2015008971A (en) Pyrido- or pyrrolo-fused pyrimidine derivatives as autotaxin inhibitors for treating pain.
ATE487474T1 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EA201000017A1 (en) PRELIMINARY COMPOSITION OF SULFUR CEMENT AND METHOD OF PREPARATION OF PRELIMINARY COMPOSITION OF SULFUR CEMENT
TW200637559A (en) 3-propenylcefem derivative
AR031597A1 (en) PIPERIDINE COMPOUNDS, A PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITIONS, AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR USE AS CCR-3 INHIBITORS
RU2020108470A (en) ADDITIVE COMPOSITION FOR CULTURAL ENVIRONMENT, ADDITIVE COMPOUND FOR CULTURAL ENVIRONMENT AND METHOD FOR CULTIVATION OF CELLS OR TISSUES USING THIS COMPOSITION AND COMPOUND
RU2328490C2 (en) Benzoxazinone derivatives and based on them pharmaceutical composition
MX2014004144A (en) Ethynyl derivatives as mglur5 allosteric modulators.
RU2009125439A (en) COMBINATION OF AN INHIBITOR WHEN AND ANTIMETABOLITIS
ATE450496T1 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
ATE479690T1 (en) THIENOÄ2,3-BÜPYRIDINE DERIVATIVES
MY144609A (en) 2-methyl-4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives
EA202191370A1 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS PREPARATION
HUP0201357A2 (en) Asymmetric copper complex, its preparation and process for preparing cyclopropan carboxylate derivatives using the same